Target intelligence / Profile preview

MicroRNA 101-2 (miR-101-2)

Target
miR-101-2
Molecular classification
MicroRNA, Non-coding RNA
01

Overview

MicroRNA 101-2 is a highly conserved, small non-coding RNA encoded in the human genome at chromosome 9p24.1, serving as one of two precursor transcripts for mature miR-101. It regulates gene expression post-transcriptionally by binding the 3’UTR of target messenger RNAs, resulting in mRNA degradation or translation inhibition. MiR-101-2 frequently acts as a tumor suppressor, directly repressing multiple oncogenes (e.g., EZH2, COX-2, MCL-1, FOS, USP47, KPNA2) and is involved in critical biological processes such as inhibiting cell proliferation, migration, invasion, and promoting apoptosis. The molecule is notably downregulated in a range of malignancies and other progressive diseases including fibrotic and cardiovascular conditions, making its restoring a potential approach in miRNA-based therapeutics and biomarker development.

Other names
hsa-mir-101-2MIRN101-2mir-101-2MIR101-2
02

Mechanism of action

Restoration or overexpression of miR-101-2 inhibits oncogenic targets (EZH2, COX-2, MCL-1, FOS, USP47, KPNA2), leading to suppression of tumor proliferation, migration, invasion, and promotion of apoptosis. miR-101-2 mimics act as gene therapy agents to modulate downstream gene expression.

03

Biological functions

Regulation of gene expression at transcriptional and post-transcriptional levelsCell proliferationCell apoptosisCell migrationCell invasionEpithelial-mesenchymal transition (EMT)Protein degradation regulation
04

Disease associations

Cancer (acts as a tumor suppressor, involved in gastric, cervical, endometrial, hepatocellular, lung, oral, bladder, and other cancers)Fibrosis (pulmonary, hepatic)Cardiovascular diseasesCerebrovascular diseases
05

Safety considerations

Challenges in delivery and specificity for therapeutic miRNA mimicsPotential off-target effects due to broad gene regulation by microRNAs
06

Interacting drugs

Paclitaxel
07

Biomarkers

Downregulation of miR-101-2 (low expression) predicts poor prognosis in various cancersmiR-101-2 expression levels can serve as biomarkers for cancer diagnosis, prognosis, and monitoring therapy efficacy

Beyond the preview

Go deeper on MicroRNA 101-2 (miR-101-2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 101-2 (miR-101-2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call